Better Therapeutics Insiders
BTTXDelisted Stock | USD 0.73 0.04 5.19% |
Better Therapeutics employs about 54 people. The company is managed by 12 executives with a total tenure of roughly 126 years, averaging almost 10.0 years of service per executive, having 4.5 employees per reported executive. Break down of Better Therapeutics' management performance can provide insight into the company performance.
Frank Karbe CEO Interim CEO |
Better |
Better Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.9505) % which means that it has lost $0.9505 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.2164) %, meaning that it created substantial loss on money invested by shareholders. Better Therapeutics' management efficiency ratios could be used to measure how well Better Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Better Therapeutics Workforce Comparison
Better Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,261. Better Therapeutics holds roughly 54.0 in number of employees claiming about 4% of equities under Health Care industry.
Better Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Better Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Better Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Better Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Perry David P over six months ago Acquisition by Perry David P of 839895 shares of Better Therapeutics subject to Rule 16b-3 | ||
Perry David P over six months ago Acquisition by Perry David P of 1471453 shares of Better Therapeutics subject to Rule 16b-3 | ||
Miller Leslie A over six months ago Acquisition by Miller Leslie A of 3587 shares of Better Therapeutics subject to Rule 16b-3 | ||
Miller Leslie A over six months ago Better Therapeutics exotic insider transaction detected | ||
Frank Karbe over a year ago Purchase by Frank Karbe of 137005 shares of Better Therapeutics | ||
Lavizzomourey Risa J over a year ago Acquisition by Lavizzomourey Risa J of 15000 shares of Better Therapeutics subject to Rule 16b-3 | ||
Mark Heinen over a year ago Acquisition by Mark Heinen of 54000 shares of Better Therapeutics subject to Rule 16b-3 | ||
Frank Karbe over a year ago Purchase by Frank Karbe of 242424 shares of Better Therapeutics |
Better Therapeutics Notable Stakeholders
A Better Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Better Therapeutics often face trade-offs trying to please all of them. Better Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Better Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Frank Karbe | Interim CEO | Profile | |
Thiago Oliveira | Chief Officer | Profile | |
Angela Willis | Senior Access | Profile | |
Kevin Appelbaum | CoFounder Director | Profile | |
Jessica Meng | Chief Officer | Profile | |
Mark MD | Chief Officer | Profile | |
Mark Heinen | Head CFO | Profile | |
Kristin Wynholds | Chief Officer | Profile | |
Leslie Miller | Controller | Profile | |
Andres Camacho | Senior Engineering | Profile | |
David MBA | CoFounder Chairman | Profile | |
Diane GomezThinnes | Chief Officer | Profile |
About Better Therapeutics Management Performance
The success or failure of an entity such as Better Therapeutics often depends on how effective the management is. Better Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Better management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Better management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California. Better Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people.
The data published in Better Therapeutics' official financial statements typically reflect Better Therapeutics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Better Therapeutics' quantitative information. For example, before you start analyzing numbers published by Better accountants, it's essential to understand Better Therapeutics' liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the imprecision that can be found in Better Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Better Therapeutics. Check Better Therapeutics' Beneish M Score to see the likelihood of Better Therapeutics' management manipulating its earnings.
Better Therapeutics Workforce Analysis
Traditionally, organizations such as Better Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Better Therapeutics within its industry.Better Therapeutics Manpower Efficiency
Return on Better Therapeutics Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 584.7K | |
Net Loss Per Executive | 2.6M | |
Working Capital Per Employee | 91.7K | |
Working Capital Per Executive | 412.7K |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Better OTC Stock
If you are still planning to invest in Better Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Better Therapeutics' history and understand the potential risks before investing.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Transaction History View history of all your transactions and understand their impact on performance | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |